Management of Severe Chemotherapy-induced Neutropenia in Advanced Breast Cancer

EC-18 for Management of Chemotherapy-Induced Neutropenia in Patients With Advanced BC Receiving Low Febrile Neutropenia Risk Chemotherapy: Dose-Escalation, Open-label, Trial to Assess Safety and Tolerability of EC-18

To assess the safety and establish the dose to assess the pharmacokinetic activity following administration of EC-18 in patients with advanced breast cancer receiving low febrile neutropenia risk chemotherapy who are the candidates for second-line or higher combination therapy with doxorubicin and cyclophosphamide.

Study Overview

• Status: Completed
• Conditions: Febrile Neutropenia
• Intervention / Treatment: Drug: EC-18

Detailed Description

This study will utilize a non-randomized, open-label 3 + 3 dose escalation design in which subjects will receive 500 mg, 1000 mg, 1500 mg, 2000 mg, 3000 mg and 4000mg of EC-18. The stepwise daily dosing by cohort was performed for 21 days (3 weeks)

• Study Type: Interventional
• Enrollment (Actual): 28
• Phase: Phase 2; Phase 1

Contacts and Locations

Study Locations

• Korea, Republic of
  • Gyeonggi-do, Korea, Republic of, 10408
    • National Cancer Center
  • Seoul, Korea, Republic of, 03722
    • Yonsei University Health System Severance Hospital
  • Seoul, Korea, Republic of, 05505
    • Asan Medical Center

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 19 years to 85 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Women ≥19 years of age
2. Subjects who have voluntarily signed the informed consent prior to the screening tests to participate in the study
3. Subjects who have been diagnosed as adenocarcinoma of the breast and relapsed after adjuvant or primary (neoadjuvant) chemotherapy, and was confirmed based on documented medical history to be candidates for second-line or higher combination chemotherapy with doxorubicin and cyclophosphamide to treat relapsed or metastatic disease.

4. Subjects with adequate function of major organs based on the following clinical laboratory values in the latest test performed within 28 days prior to IP dosing:

   • Neutrophil count (ANC): ≥1,500/mm3
   • Platelet count: ≥10.0×10^4/mm3
   • Hemoglobin: ≥9.0 g/dL
   • AST, ALT: ≤3.0 x ULN
   • Serum total bilirubin: ≤1.5 mg/dL
   • Serum creatinine: ≤1.5 mg/dL
5. Subjects whose Eastern Cooperative Oncology Group (ECOG) performance score is 0-1.
6. For women of child bearing potential, subjects should have willingness to use acceptable contraceptive methods during the entire clinical study period.
7. Subjects who are capable of understanding the overall procedure of the clinical study and are willing to participate in compliance with all test procedures.

Exclusion Criteria:

1. Subjects with active and inactive hepatitis, patients with history of HIV, or other uncontrolled infectious disease.
2. Subjects with a history of HIV positive or currently undergoing/received antiretroviral therapy, and subjects with a history of hepatitis B surface antigen positive, or current positive hepatitis C disease.
3. Subjects who received radiation therapy within 4 weeks prior to assignment to treatment group.
4. Subjects who have been diagnosed within 5 years with other types of cancer except for those who have been appropriately treated for superficial non-melanoma skin cancer or cervical intraepithelial neoplasia.
5. Subjects with a history of intolerance for granulocyte colony stimulating factor treatment
6. Subjects who are expected to show hypersensitivity to the IP or its ingredients
7. Subjects with a positive urine pregnancy test result at screening visit or before the first administration of the study drug
8. Subjects who took any other investigational product in other clinical study within 30 days prior to screening visit.
9. Clinically significant unstable medical abnormality; psychiatric disorder, chronic disease, alcohol or drug use disorder, or other significant biological, psychological, or social factor, which in the investigator's opinion, unfavorably affects the risk-benefit ratio of study participation or likely to affect study results.
10. Subjects with heart disease (i.e. congestive heart failure, arrhythmia, symptomatic coronary artery disease); Myocardial infarction within 6 months before initiation of the study.
11. Subjects with left ventricular ejection fraction (LVEF) < 50% at screening.
12. Significant neurological or psychiatric disorders including dementia or seizures.
13. Patients with dyslipidemia not controlled by drugs [based on LDL-C and TG levels for which treatment is recommended by the Korean dyslipidemia treatment guidelines and the U.S. National Cholesterol Education Program-Adult Treatment Panel III]
14. Uncontrolled diabetes mellitus (HbA1c >7%; if the level is confirmed after 6 months or longer treatment with oral hypoglycemic agents or insulin)
15. Subjects who have received systemic chemotherapy with doxorubicin to treat metastatic or recurrent breast cancer
16. Subjects with grade 2 or higher peripheral sensory neuropathy at screening visit or before the first dosing of the study drug
17. Subjects who have undergone significant gastrectomy along with intractable nausea and vomiting, chronic gastrointestinal disease, or clinically significant sequelae, which would interfere with proper absorption of the study drug
18. Subjects who administered systemic antibiotics within 14 days prior to administration of the study drug
19. Subjects whose cumulative dose of doxorubicin exceeded 240 mg/m2
20. Subjects who were currently receiving trastuzumab

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Sequential Assignment
• Masking: None (Open Label)

Number of Arms

6

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Cohort 1; EC-18 500 mg	Drug: EC-18; oral administration; Other Names: EC-18 soft capsules
Experimental: Cohort 2; EC-18 1000 mg	Drug: EC-18; oral administration; Other Names: EC-18 soft capsules
Experimental: Cohort 3; EC-18 1500 mg	Drug: EC-18; oral administration; Other Names: EC-18 soft capsules
Experimental: Cohort 4; EC-18 2000 mg	Drug: EC-18; oral administration; Other Names: EC-18 soft capsules
Experimental: Cohort 5; EC-18 3000 mg	Drug: EC-18; oral administration; Other Names: EC-18 soft capsules
Experimental: Cohort 6; EC-18 4000 mg	Drug: EC-18; oral administration; Other Names: EC-18 soft capsules

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Duration of Grade 4 neutropenia	Complete blood count and absolute neutrophil count assessed daily to determine febrile neutropenia	15 days after starting chemotherapy

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Incidence of Grade 3-4 neutropenia	The grade for Neutropenia is assessed according to NCI CTCAE 4.03 version	For 15 days after starting chemotherapy (except Day 3 and 4)
Incidence of febrile neutropenia	Febrile neutropenia is assessed by ANC and body temperature according to NCI CTCAE version 4.03	For 15 days after starting chemotherapy (except Day 3 and 4)

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Incidence of adverse events	Incidence of treatment-emergent adverse events, serious adverse events, adverse events leading to discontinuation, adverse events by severity grade	3-week treatment period and follow-up visit at day 36
Clinical laboratory evaluations	Clinical laboratory tests (hematology, clinical chemistry, coagulation, and urine test result analysis) -- absolute values and changes from the baseline	3-week treatment period and follow-up visit at day 36
Vital signs	Absolute values and changes from baseline in vital signs	3-week treatment period and follow-up visit at day 36
12-lead electrocardiogram (ECG)	Absolute values and changes from baseline ECG	3-week treatment period and follow-up visit at day 36

Collaborators and Investigators

• Sponsor: Enzychem Lifesciences Corporation
• Investigators: Principal Investigator: Sung-Bae Kim, MD, PhD, Asan Medical Center

Study record dates

Study Major Dates

• Study Start (Actual): October 30, 2017
• Primary Completion (Actual): November 26, 2019
• Study Completion (Actual): December 5, 2019

Study Registration Dates

• First Submitted: February 24, 2017
• First Submitted That Met QC Criteria: April 1, 2017
• First Posted (Actual): April 7, 2017

Study Record Updates

• Last Update Posted (Actual): August 15, 2023
• Last Update Submitted That Met QC Criteria: August 13, 2023
• Last Verified: August 1, 2023

More Information

Terms related to this study

• Keywords: EC-18, febrile neutropenia, breast cancer, chemotherapy
• Additional Relevant MeSH Terms: Wounds and Injuries; Hematologic Diseases; Agranulocytosis; Leukopenia; Leukocyte Disorders; Body Temperature Changes; Heat Stress Disorders; Neutropenia; Hyperthermia; Fever; Febrile Neutropenia
• Other Study ID Numbers: EC-18-201

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No